There were 735 press releases posted in the last 24 hours and 166,715 in the last 365 days.

Michael A. Nemzek appointed as MedGenome Chief Commercial Officer

Key appointment to strengthen company’s expansion efforts

FOSTER CITY, CA, UNITED STATES, January 9, 2017 / -- MedGenome, a genomics-driven research and diagnostics company based in Foster City, California, today announced the appointment of Michael A. Nemzek as its Chief Commercial Officer.

Mr. Nemzek has held executive senior leadership team positions in both public companies and a number of private companies that have become successful public companies by merger and acquisition. He has played a major role in generating significant revenues during his prior executive positions at life-science companies including RareCyte, Affymetrix and Velocity11. Mr. Nemzek holds advanced degrees in chemistry from North Carolina State University and in management from the University of Maryland University College.

“It’s a pleasure to welcome Michael as CCO of MedGenome. He is proven leader who has the experience and track record to deliver results. As we grow our offerings to customers, his addition to the US based leadership team will strengthen our expansion” said Sam Santhosh, Global CEO, MedGenome.

About MedGenome

MedGenome ( is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome. MedGenome has a CLIA / CAP certified NGS lab in Foster City, CA and offers NGS Informatics services along with sequencing services. MedGenome is also a market leader for genomic diagnostics in South Asia. It is a founding member of GenomeAsia 100K initiative to sequence 100,000 genomes in South, North and East Asia.

Forward-looking Statements:

This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

MedGenome Inc
email us here